MedTrace Logo

Anti-CGRP Monoclonal Antibody Response After Switching (AMARAS)

NCT05785988 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-02-14

No results posted yet for this study

Summary

Monoclonal antibodies targeting calcitonin gene-related peptide (mAb-CGRP) have shown efficacy and effectiveness in the treatment of episodic and chronic migraine, however, not all patients respond to them. Preliminary data suggests that some patients who failed to one of them, may respond to a different anti-CGRP monoclonal antibody.

Observational analytic study with a retrospective cohort design including patients treated with a second mAb-CGRP due to lack of response to the first one.

The aim of this study is to provide Class II evidence about the effectiveness and tolerability of the mAb-CGRP switching in patients with migraine, treated in a real-world setting.

Conditions

Sponsors & Collaborators

  • Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León

    collaborator OTHER

  • Hospital Clínico Universitario de Valladolid

    lead OTHER

Principal Investigators

  • David García Azorín, MD, PhD · Research coordinator

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2024-11-10
Completion
2024-11-10

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05785988 on ClinicalTrials.gov